Jorey Chernett, a 10% owner of Neuronetics, Inc. (NASDAQ:STIM), acquired 35,000 shares of common stock in the company on July 14, 2026. The total value of this transaction amounted to $62,300.
The shares were purchased at a weighted average price of $1.78 per share. According to the filing, these shares were bought in multiple transactions with prices ranging from $1.77 to $1.79 per share. Following this acquisition, Mr. Chernett directly holds 10,588,988 shares of Neuronetics common stock. The purchase comes as the stock has posted a 15% return over the past week, though InvestingPro analysis suggests the shares are currently trading above their Fair Value of $1.71. The company, with a market cap of $124.49 million, remains unprofitable with a negative EPS of $0.55 over the last twelve months, though it has demonstrated strong revenue growth of 70%.
This filing was made public on July 15, 2026. For investors seeking deeper insights, InvestingPro offers a comprehensive Pro Research Report on STIM, one of 1,400+ US equities covered, along with additional ProTips and advanced metrics to guide investment decisions.
In other recent news, Neuronetics Inc. reported its Q1 2026 earnings, showing revenue of $34.5 million, which exceeded expectations of $34.18 million. However, the company did not meet its earnings per share (EPS) forecast, reporting -$0.16 compared to the anticipated -$0.13. In a separate development, Neuronetics announced a partnership with ANT Neuro to integrate neuronavigation technology into its NeuroStar Advanced Therapy System, enhancing treatment delivery with real-time spatial tracking and 3D visualization. Additionally, Neuronetics updated its consulting agreement with Francis X. Brown III, who will continue as Interim Principal Financial and Accounting Officer until a full-time officer is appointed. These recent developments reflect Neuronetics’ ongoing efforts to improve its financial performance and expand its technological capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.